Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is a radiopharmaceutical-focused life sciences company dedicated to developing, manufacturing, and commercializing innovative diagnostic imaging agents and therapeutic products. The company's mission is to deliver life-changing science that enables clinicians to "Find, Fight and Follow" diseases, ultimately improving patient outcomes. Lantheus is headquartered in Bedford, Massachusetts.

Lantheus' product portfolio is categorized into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Key products include PYLARIFY, a leading PET imaging agent for prostate cancer; DEFINITY, a microbubble ultrasound enhancing agent for cardiac imaging; and TechneLite, a technetium generator used in nuclear medicine procedures. The company also offers Neuraceq, a beta-amyloid targeted radiodiagnostic for Alzheimer's disease, and is advancing a pipeline of next-generation diagnostic and therapeutic candidates. Lantheus serves a broad customer base, including hospitals, clinics, diagnostic imaging centers, and radiopharmacies.

In recent developments, Lantheus received FDA approval for PYLARIFY TruVu™ (piflufolastat F 18) Injection in March 2026, and a tentative FDA approval for Lutetium Lu 177 Dotatate (PNT2003) in the same month. The company also saw a three-month extension of the PDUFA date for its diagnostic imaging kit LNTH-2501 to June 2026. Leadership changes include Mary Anne Heino's appointment as CEO in January 2026. Strategically, Lantheus has expanded its capabilities through acquisitions, including Life Molecular Imaging in July 2025 and Evergreen Theragnostics in Q2 2025, reinforcing its strong market position in radiopharmaceuticals, particularly in prostate cancer imaging where PYLARIFY achieved blockbuster status in 2024.